Clinical Trials Directory

Trials / Completed

CompletedNCT01439295

Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia

Urinary Ascorbyl Peroxide as an Early Biological Marker of Bronchopulmonary Dysplasia in Preterm Infants Less Than 33 Weeks of Gestation

Status
Completed
Phase
Study type
Observational
Enrollment
51 (actual)
Sponsor
St. Justine's Hospital · Academic / Other
Sex
All
Age
23 Weeks – 32 Weeks
Healthy volunteers
Not accepted

Summary

Urinary ascorbyl peroxide level in the first week of life will be a good predictor of Bronchopulmonary dysplasia (BPD) in preterm infants less than 33 weeks of gestation.

Detailed description

This study uses ascorbyl peroxide as representative of oxidative stress in premature infants on parenteral nutrition and aims to test the correlation of this metabolite and the different major neonatal outcomes 'mainly bronchopulmonary dysplasia).

Conditions

Timeline

Start date
2010-08-01
Primary completion
2015-11-01
Completion
2015-11-01
First posted
2011-09-23
Last updated
2015-11-18

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01439295. Inclusion in this directory is not an endorsement.